We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




New Blood Test Helps Detect Brain Injury in Minutes

By LabMedica International staff writers
Posted on 11 Sep 2019
Print article
Image: The i-STAT Alinity system integrates with-patient testing directly into the patient-care pathway, accelerating time to treatment, improving quality and increasing access to care (Photo courtesy of Abbott).
Image: The i-STAT Alinity system integrates with-patient testing directly into the patient-care pathway, accelerating time to treatment, improving quality and increasing access to care (Photo courtesy of Abbott).
After traumatic brain injury (TBI), plasma concentration of glial fibrillary acidic protein (GFAP) correlates with intracranial injury visible on computerized axial tomography (CT) scan. Some patients with suspected TBI with normal CT findings show pathology on magnetic resonance imaging (MRI).

Recently scientists have found that a handheld blood analyzer could help detect brain injury within 15 minutes using a commercial system that measures GFAP and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) proteins from the brain that are released into the blood after a brain injury, They assessed the discriminative ability of GFAP to identify MRI abnormalities in patients with normal CT findings.

Neurologists at the University of California at San Francisco (San Francisco, CA, USA) and their associates enrolled patients with TBI who had a clinically indicated head CT scan within 24 hours of injury at 18 level 1 trauma centers in the USA. For this analysis, they included patients with normal CT findings (Glasgow Coma Scale score 13–15) who consented to venipuncture within 24 hours post injury and who had a MRI scan 7–18 days post injury. They compared MRI findings in these patients with those of orthopedic trauma controls and healthy controls recruited from the study sites.

Plasma GFAP concentrations (pg/mL) were measured using a prototype assay on a point-of-care platform, the hand-held blood analyzer, the i-STAT Alinity system. The scientists used receiver operating characteristic (ROC) analysis to evaluate the discriminative ability of GFAP for positive MRI scans in patients with negative CT scans over 24 hours (time between injury and venipuncture). The primary outcome was the area under the ROC curve (AUC) for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings within 24 hours of injury.

The team recruited between February 26, 2014, and June 15, 2018, 450 patients with normal head CT scans (of whom 330 had negative MRI scans and 120 had positive MRI scans), 122 orthopedic trauma controls, and 209 healthy controls. AUC for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings was 0·777 over 24 hours. Median plasma GFAP concentration was highest in patients with CT-negative and MRI-positive findings (414.4 pg/mL), followed by patients with CT-negative and MRI-negative findings (74.0 pg/mL), orthopedic trauma controls (13.1 pg/mL), and healthy controls (8.0 pg/mL, all comparisons between patients with CT-negative MRI-positive findings and other groups.

The authors concluded that analysis of blood GFAP concentrations using prototype assays on a point-of-care platform within 24 hours of injury might improve detection of TBI and identify patients who might need subsequent MRI and follow-up. The study was published on August 23, 2019, in the journal The Lancet Neurology.

Related Links:
University of California at San Francisco

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.